Predictors of insulin resistance and the effect of Metformin treatment in obese pediatric patients
Predictors of insulin resistance and the effect of Metformin treatment in obese pediatric patients
Gallen H*, Banerjee I**, Clayton PE***, Ehtisham S****, Padidela R*****, Patel L******, Skae M*******
MUMPS Conference, October 2015, UK*, MUMPS Conference, October 2015, UK**, MUMPS Conference, October 2015, UK***, MUMPS Conference, October 2015, UK****, MUMPS Conference, October 2015, UK*****, MUMPS Conference, October 2015, UK******, MUMPS Conference, October 2015, UK*******
Paediatric obesity is a growing concern for the health service. There is currently no consensus for routine screening of metabolic profiles and medical treatment in obese paediatric patients.
We aimed to determine medium-term outcomes of metformin treatment on body mass index (BMI), glucose and insulin levels in obese paediatric patients. In a retrospective review, data were collected from obese paediatric patients on metformin for insulin resistance between October 2009 and October 2014. Changes in BMI SDS, glucose and insulin were analysed. Paired sample t-tests were used to compare pre and post treatment results (treatment washout period of 1 month).
Seventy patients were treated with metformin (50=female) (35=British White, 18=Pakistani) at a mean age of 12.7 (6.1-17.2) years. Mean BMI was 35.2 (24.2-48.5 kg/m2) and BMI SDS was 3.4 (2.2-4.7). All patients with a family history of Type 2 diabetes mellitus (DM) had acanthosis nigricans (AN). All patients with AN (n=43, 49% with no family history of T2 DM) had insulin resistance with significantly higher basal insulin levels (p<0.05) than those without. Metformin was associated with reduced BMI z-score at 6-12 months (-0.1 SDS, p<0.05) and 18-24 months (-0.2 SDS, p<0.05). Reduction in fasting and postprandial glucose levels were (-0.1 mmol/L, p=0.17) and (-0.5 mmol/L, p=0.17) respectively, with a significant reduction in postprandial glucose levels in those patients with impaired glucose tolerance (n=13) (-1.9 mmol/L, p<0.05). Metformin was associated with a reduction in fasting insulin (-3.0 mU/L,p=0.44), and significantly reduced 2 hour insulin (-118.0 mU/L ,p<0.05) after treatment for 12-18 months.
Metformin treatment is significantly associated with reduction in BMI z-score from 6 months and reduced postprandial insulin levels after treatment. It should be considered as a treatment modality in normoglycaemic obese paediatric patients for weight stabilisation and improvement of insulin resistance, which may have longer term implications on metabolic health.
How to Cite URL :
H G, I B, PE C, S E, R P, L P, M S.. Available From : Conference_abstracts/report.aspx?reportid=841
Advertisements by :    Mega-CV by Aristo IndoIV by Sun Pharma
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.